Ole‐Bjørn Tysnes

12.6k total citations · 4 hit papers
192 papers, 8.3k citations indexed

About

Ole‐Bjørn Tysnes is a scholar working on Neurology, Molecular Biology and Physiology. According to data from OpenAlex, Ole‐Bjørn Tysnes has authored 192 papers receiving a total of 8.3k indexed citations (citations by other indexed papers that have themselves been cited), including 140 papers in Neurology, 28 papers in Molecular Biology and 28 papers in Physiology. Recurrent topics in Ole‐Bjørn Tysnes's work include Parkinson's Disease Mechanisms and Treatments (109 papers), Neurological disorders and treatments (40 papers) and Amyotrophic Lateral Sclerosis Research (28 papers). Ole‐Bjørn Tysnes is often cited by papers focused on Parkinson's Disease Mechanisms and Treatments (109 papers), Neurological disorders and treatments (40 papers) and Amyotrophic Lateral Sclerosis Research (28 papers). Ole‐Bjørn Tysnes collaborates with scholars based in Norway, United Kingdom and United States. Ole‐Bjørn Tysnes's co-authors include Anette Storstein, Jan Larsen, Guido Alves, Kenn Freddy Pedersen, Dag Aarsland, Kolbjørn Brønnick, Holm Holmsen, Karen Herlofson, Charalampos Tzoulis and Kristoffer Haugarvoll and has published in prestigious journals such as Journal of Biological Chemistry, Nature Communications and PLoS ONE.

In The Last Decade

Ole‐Bjørn Tysnes

183 papers receiving 8.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Epidemiology of Parkinson’s disease

2017 1.7k citations Ole‐Bjørn Tysnes et al. profile →
Cognitive impairment in incident, untreated Parkinson disease

2008 510 citations Dag Aarsland, Kolbjørn Brønnick et al. Neurology profile →
The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson’s disease

2022 186 citations Christian Dölle, Gonzalo S. Nido et al. profile →
European Academy of Neurology (EAN) guideline on the management of amyotrophic lateral sclerosis in collaboration with European Reference Network for Neuromuscular Diseases (ERNEURO‐NMD)

2024 43 citations Philip Van Damme, Ammar Al‐Chalabi et al. European Journal of Neurology profile →

Peers

Countries citing papers authored by Ole‐Bjørn Tysnes

Since Specialization

Citations

This map shows the geographic impact of Ole‐Bjørn Tysnes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ole‐Bjørn Tysnes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ole‐Bjørn Tysnes more than expected).

Fields of papers citing papers by Ole‐Bjørn Tysnes

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ole‐Bjørn Tysnes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ole‐Bjørn Tysnes. The network helps show where Ole‐Bjørn Tysnes may publish in the future.

Co-authorship network of co-authors of Ole‐Bjørn Tysnes

This figure shows the co-authorship network connecting the top 25 collaborators of Ole‐Bjørn Tysnes. A scholar is included among the top collaborators of Ole‐Bjørn Tysnes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ole‐Bjørn Tysnes. Ole‐Bjørn Tysnes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Cerebrospinal Fluid Phosphorylated Alpha‐Synuclein in Newly Diagnosed Parkinson's Disease 2025 ·European Journal of Neurology ·(unknown), Guido Alves, Ole‐Bjørn Tysnes, Jodi Maple‐Grødem, Johannes Lange	0
2	Single-nucleus transcriptomics reveals disease- and pathology-specific signatures in α-synucleinopathies 2024 ·Brain ·Gonzalo S. Nido, (unknown), (unknown), Anna Rubiolo, (unknown), Guido Alves, Ole‐Bjørn Tysnes, (unknown), Christian Dölle, Charalampos Tzoulis	0
3	Mitochondrial complex I deficiency stratifies idiopathic Parkinson’s disease 2024 ·Nature Communications ·Irene H. Flønes, Lilah Toker, (unknown), (unknown), (unknown), (unknown), (unknown), Erika Fernández‐Vizarra, Cèlia Painous, Alexandra Pérez‐Soriano, Yaroslau Compta, Laura Molina‐Porcel, Guido Alves, Ole‐Bjørn Tysnes, Christian Dölle, Gonzalo S. Nido, Charalampos Tzoulis	19
4	Serum neurofilament light at diagnosis: a prognostic indicator for accelerated disease progression in Parkinson’s Disease 2024 ·npj Parkinson s Disease ·(unknown), (unknown), Guido Alves, Ole‐Bjørn Tysnes, Kaj Blennow, (unknown), Jodi Maple‐Grødem, Johannes Lange	8
5	European Academy of Neurology (EAN) guideline on the management of amyotrophic lateral sclerosis in collaboration with European Reference Network for Neuromuscular Diseases (ERNEURO‐NMD) breakdown → 2024 ·European Journal of Neurology ·Philip Van Damme, Ammar Al‐Chalabi, Peter M. Andersen, Adriano Chiò, Philippe Couratier, Mamede de Carvalho, Orla Hardiman, Magdalena Kuźma‐Kozakiewicz, Albert C. Ludolph, Christopher McDermott, Jesús S. Mora, Susanne Petri, Katrin Probyn, (unknown), François Salachas, Vincenzo Silani, Ole‐Bjørn Tysnes, Leonard H. van den Berg, Gemma Villanueva, Markus Weber	43
6	Norwegian version of the Edinburgh cognitive and behavioural ALS screen: Construct validity, internal consistency, inter-rater, and test-retest reliability 2023 ·PLoS ONE ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Ole‐Bjørn Tysnes, Jörg Aßmus, Tiina Rekand	0
7	Seed Amplification Assay as a Diagnostic Tool in Newly-Diagnosed Parkinson’s Disease 2023 ·Journal of Parkinson s Disease ·(unknown), Jodi Maple‐Grødem, Ole‐Bjørn Tysnes, Guido Alves, Johannes Lange	8
8	Inflammatory Biomarkers in Newly Diagnosed Patients With Parkinson Disease and Related Neurodegenerative Disorders 2023 ·Neurology Neuroimmunology & Neuroinflammation ·(unknown), Anastasia Ushakova, Ragnhild Eide Skogseth, Guido Alves, Ole‐Bjørn Tysnes, Dag Aarsland, Johannes Lange, Jodi Maple‐Grødem	18
9	Frailty in Parkinson's disease and its association with early dementia: A longitudinal study 2022 ·Parkinsonism & Related Disorders ·Miguel Germán Borda, Mario Ulises Pérez‐Zepeda, (unknown), К. Ray Chaudhuri, Diego Tovar, Lindsay Wallace, Lucia Batzu, Kenneth Rockwood, Ole‐Bjørn Tysnes, Dag Aarsland, Guido Alves	14
10	Use of Off-Label Drugs and Nutrition Supplements among Patients with Amyotrophic Lateral Sclerosis in Norway 2022 ·Neurology Research International ·(unknown), Ole‐Bjørn Tysnes, Tale L. Bjerknes	1
11	Lack of Association Between GBA Mutations and Motor Complications in European and American Parkinson's Disease Cohorts 2021 ·Duo Research Archive (University of Oslo) ·Jodi Maple‐Grødem, Kimberly C. Paul, Ingvild Dalen, Kathie J. Ngo, Darice Y. Wong, Angus D. Macleod, Carl Counsell, David Bäckström, Lars Forsgren, Ole‐Bjørn Tysnes, Cynthia Kusters, Brent L. Fogel, Jeff M. Bronstein, Beate Ritz, Guido Alves	5
12	Translation, cultural adaptation, and validation of a screening test for cognitive and behavioural changes in amyotrophic lateral sclerosis 2021 ·Disability and Rehabilitation ·(unknown), (unknown), Jörg Aßmus, Ole‐Bjørn Tysnes, Tiina Rekand	5
13	Combinatory microRNA serum signatures as classifiers of Parkinson's disease 2019 ·Parkinsonism & Related Disorders ·Ketan S. Patil, Indranil Basak, Ingvild Dalen, Esthelle Hoedt, Johannes Lange, (unknown), Ying Liu, Ole‐Bjørn Tysnes, Lars Forsgren, Dag Aarsland, Thomas A. Neubert, Jan Larsen, Guido Alves, Simon Geir Møller	28
14	Loss of independence in early Parkinson disease 2016 ·Neurology ·(unknown), Ole‐Bjørn Tysnes, Jan Larsen, Guido Alves	37
15	Defective mitochondrial DNA homeostasis in the substantia nigra in Parkinson disease 2016 ·Nature Communications ·Christian Dölle, Irene H. Flønes, Gonzalo S. Nido, Hrvoje Miletić, (unknown), (unknown), Peer K. Lilleng, Jan Larsen, Ole‐Bjørn Tysnes, Kristoffer Haugarvoll, Laurence A. Bindoff, Charalampos Tzoulis	196
16	White Matter Hyperintensities in Mild Lewy Body Dementia 2012 ·Dementia and Geriatric Cognitive Disorders Extra ·Ketil Oppedal, Dag Aarsland, Michael Firbank, Hogne Sønnesyn, Ole‐Bjørn Tysnes, John T. O’Brien, Mona K. Beyer	19
17	Verbal memory in drug-naive, newly diagnosed Parkinson's disease. The retrieval deficit hypothesis revisited. 2010 ·Neuropsychology ·Kolbjørn Brønnick, (unknown), Guido Alves, Dag Aarsland, Ole‐Bjørn Tysnes, Jan Larsen	79
18	Caregiver distress associated with neuropsychiatric problems in patients with early Parkinson’s disease: the Norwegian ParkWest study 2010 ·Acta Neurologica Scandinavica ·(unknown), Ole‐Bjørn Tysnes, Dag Aarsland, Jan Larsen	62
19	Motoriske symptomer ved Parkinsons sykdom 2008 ·Tidsskrift for Den Norske Laegeforening ·Jan Larsen, Antonie Giæver Beiske, Svein Ivar Bekkelund, Espen Dietrichs, Ole‐Bjørn Tysnes, (unknown), Jan Aasly	2
20	[Diffusion-weighted magnetic resonance tomography--a new instrument in the diagnosis of Creutzfeldt-Jakob disease]. 2000 ·PubMed ·Fredrik Romi, (unknown), S Mörk, Ole‐Bjørn Tysnes	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact